Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Qing Yi Decoction (Qingyi Tang) is a Traditional Chinese Medicine (TCM) herbal formula primarily utilized for the treatment of acute pancreatitis. It is a multi-component decoction typically composed of several botanical ingredients, including *Radix et Rhizoma Rhei* (Dahuang), *Radix Paeoniae Alba* (Baishao), *Fructus Aurantii Immaturus* (Zhishi), *Glauber's salt* (Mangxiao), *Radix Scutellariae* (Huangqin), *Radix Aucklandiae* (Muxiang), *Fructus Bupleuri* (Chaihu), and *Corydalis Rhizoma* (Yanhusuo). The formula is thought to exert therapeutic effects by inhibiting the systemic inflammatory response, reducing the excessive secretion and activity of pancreatic enzymes (such as amylase and lipase), improving pancreatic microcirculation, and promoting gastrointestinal motility. In clinical settings, it is often administered as an adjuvant therapy alongside standard Western medical protocols. The First Affiliated Hospital of Guangxi Medical University has conducted Phase 3 clinical trials evaluating a modified version of this decoction, often administered via oral intake or rectal drip therapy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on qing yi decoction.